(Q87691280)

English

A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma

scientific article published on 16 April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

phase I clinical trial

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sadahisa Ogasawara

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Tetsuhiro Chiba

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Yoshihiko Ooka

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Naoya Kanogawa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Tenyu Motoyama

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Eiichiro Suzuki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Akinobu Tawada

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Fumihiko Kanai

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

And Osamu Yokosuka

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

16 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

32

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

762-768

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of hepatocellular carcinoma: An update

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Capecitabine for treatment of advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24737402

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-014-0097-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737402%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87691280&oldid=1751098237"